Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease

Deng, Yanqing; Zou, Weibao; Chen, Guanghui; Shangguan, Shouqin; Zhou, Faming; Jiang, Wenxin; Li, Xiaoli

doi:10.1080/00207454.2019.1635592

Cited by 7 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials have shown that regular statin use plays a significant role in preventing cerebrovascular atherosclerosis and reducing the risk of cerebrovascular accidents [ 10 ]. Atorvastatin, a statin (lipid-lowering drug), has proven to be effective in stabilizing and reversing plaques in patients with carotid atherosclerosis in combination with antiplatelet agents [ 11 – 13 ]. Furthermore, a multicentre study showed that atorvastatin significantly reduced the risk of cardiovascular and cerebrovascular accidents in patients with CP, and the risks of stroke and coronary artery accidents decreased by 33% and 43%, respectively [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial

Yao,

Wang,

Yang

et al. 2024

Trials

View full text Add to dashboard Cite

Introduction Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have been widely used in patients with macular edema (ME) secondary to retinal vein occlusion (RVO); however, recurrence is a major concern. This study aims to observe the clinical effects of atorvastatin and intravitreal therapy in the treatment of patients with branch or central RVO-ME and coexistent carotid plaques (CP). Methods and analysis A prospective randomized controlled clinical trial will be conducted. Sixty-four patients diagnosed with branch or central RVO-ME and coexistent CP will be enrolled and randomly allocated in a 1:1 ratio to the control and experimental groups. The control group will be treated with intravitreal conbercept monthly for 3 months, followed by monthly evaluation and injection of pro re nata (PRN) for 12 months, while the experimental group will be treated with oral atorvastatin 20 mg daily combined with the control group treatment. If a drop of best-corrected visual acuity (BCVA) is more than five Early Treatment Diabetic Retinopathy Study (ETDRS) letters (one line) or an increment in central subfield thickness (CSFT) of 100 μm (or a 10% increment from the previous visit), intravitreal re-treatment will be performed. Outcome measurements include CSFT, BCVA, number of injections, and incidence of adverse events during the 12-month follow-up period. Differences between groups will be evaluated using Student’s t-test, and comparisons between groups will be evaluated using repeated-measures analysis of variance. Ethics and dissemination The study has been approved by the Institutional Review Board of Nanjing Lishui People’s Hospital, Nanjing, China (approval number 2023KY0418-12, dated 18 April 2023), and has been registered on chictr.org.cn. Written informed consent will be collected from each patient and the results of this trial will be submitted to a peer-reviewed journal. Trial registration Chinese Clinical Trial Registry ChiCTR2300071359. Registered on 12 May 2023.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial

Yao,

Wang,

Yang

et al. 2024

Trials

View full text Add to dashboard Cite

show abstract

“…Cerebral ischemia-reperfusion injury (CIRI) refers to an acute cerebral dysfunction that occurs after cerebral ischemia for a certain period of time, followed by the restoration of the infarction-associated blood supply ( 1 ). The cure rate associated with CIRI is very low, accompanied by a high disability rate and a high mortality rate; and the prognosis is very poor, with the condition seriously affecting individual's health ( 2 ). CIRI is a complex multi-factorial process whose underlying mechanism is poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis

Gao

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

The endoplasmic reticulum stress (ERS) response serves an important role in cerebral ischemia-reperfusion injury (CIRI). However, to the best of the our knowledge, the effect of rosuvastatin on the ERS response in CIRI has not yet been studied. In the present study, the effect of rosuvastatin on cell damage in CIRI was investigated; furthermore, the effect of rosuvastatin on the ERS response was explored. Firstly, a hypoxia/reoxygenation (H/R)-induced cell damage model was established in PC12 cells. Cell viability was subsequently detected by a Cell Counting Kit-8 assay. A lactate dehydrogenase kit was used to detect cytotoxicity. TUNEL assay was then used to measure the extent of cell apoptosis, and western blotting was used to analyze the expression levels of the apoptosis-associated proteins Bax, Bcl-2, cleaved caspase-3 and cleaved caspase-9. In addition, western blotting was used to detect the expression levels of ERS-associated proteins, including phosphorylated (p)-protein kinase R-like endoplasmic reticulum kinase (PERK), p-eukaryotic initiation factor 2α and other proteins. Treatment with rosuvastatin led to an increased activity of H/R-induced PC12 cells and a decrease in their cytotoxicity. Rosuvastatin also led to an inhibition in apoptosis and ERS in H/R-induced PC12 cells. After administration of the ERS response activator thapsigargin (TG), TG was found to reverse the protective effect of rosuvastatin on injury of H/R-induced PC12 cells. Taken together, these findings have shown that rosuvastatin is able to protect PC12 cells from H/R-induced injury via inhibiting ERS-induced apoptosis, providing a strong theoretical basis for the use of rosuvastatin in the clinical treatment of CIRI.

show abstract

Associations among carotid plaque progression, cerebrovascular/cardiovascular diseases and LDL-C/non-HDL-C goal achievement in diabetic patients: A retrospective cohort study

Li¹,

Zhang²,

Guo³

et al. 2023

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease

Cited by 7 publications

References 14 publications

Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial

Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial

Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis

Associations among carotid plaque progression, cerebrovascular/cardiovascular diseases and LDL-C/non-HDL-C goal achievement in diabetic patients: A retrospective cohort study

Contact Info

Product

Resources

About